Driving Innovation in Biologics
Bispecific antibodies are at the center of a vibrant area in antibody engineering with a growing range of platforms that has led to numerous constructs with novel functionality. The Bispecific Antibodies stream at PEGS will showcase the latest developments
in novel platforms and engineering to optimize clinical performance and minimize adverse effects. Join the two foremost events of the year to gain a comprehensive view of bispecific antibodies, network with leaders in the industry and hear about the
latest clinical results.
Conferences Include:
May 11-12
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
May 12-13
Engineering Bispecific Antibodies
Recommended Short Course:
SC3: Developability of Bispecific Antibodies: Formats and Applications
Instructor: Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Keynote Speakers:
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals
Gary J. Nabel, MD, PhD, Former CSO, Sanofi
Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center